- Report
- February 2024
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- November 2023
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 204 Pages
Global
From €4574EUR$4,750USD£3,934GBP
- Report
- November 2019
- 150 Pages
Global
From €1324EUR$1,375USD£1,139GBP
€2648EUR$2,750USD£2,278GBP
- Report
- April 2018
- 168 Pages
Global
From €1324EUR$1,375USD£1,139GBP
€2648EUR$2,750USD£2,278GBP
- Report
- January 2021
- 900 Pages
United States
From €3178EUR$3,300USD£2,733GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €482EUR$500USD£414GBP
- Report
- January 2019
- 35 Pages
Global
From €963EUR$1,000USD£828GBP
- Report
- September 2019
Global
From €5171EUR$5,370USD£4,448GBP
Gemzar (gemcitabine) is a chemotherapy drug used to treat a variety of cancers, including lung cancer. It is a nucleoside analog, meaning it works by interfering with the growth of cancer cells. Gemzar is typically used in combination with other drugs, such as cisplatin or carboplatin, to treat advanced or metastatic non-small cell lung cancer (NSCLC). It is also used to treat small cell lung cancer (SCLC) and mesothelioma.
Gemzar is a widely used drug in the lung cancer market, and is often prescribed as a first-line treatment for NSCLC. It is also used in combination with other drugs to treat more advanced stages of the disease. The drug is available in both generic and brand-name formulations, and is typically administered intravenously.
The Gemzar market is highly competitive, with a number of companies offering the drug. These include Eli Lilly, Bristol-Myers Squibb, Merck, Pfizer, and AstraZeneca. Show Less Read more
